Novacyt (ALNOV.PA) Aktie Kurs

Novacyt SA primarily operates in the healthcare and biotechnology industries.

The main competitors of Novacyt SA in the market include companies such as PerkinElmer, Inc., Quidel Corporation, and Abbott Laboratories.

Novacyt SA is a renowned biotechnology company specializing in clinical diagnostics. Founded in 2006, Novacyt has since emerged as a global leader in the field. With a strong focus on research and development, the company has developed innovative solutions for the rapid detection and diagnosis of infectious diseases and various types of cancer. Novacyt's cutting-edge technology has gained recognition worldwide, enabling accurate and timely results. Through strategic partnerships and collaborations, Novacyt continues to expand its product portfolio and enhance its presence in international markets. With a commitment to improving global healthcare, Novacyt SA remains at the forefront of innovative diagnostics solutions.

Novacyt SA has achieved several significant milestones. Notably, the company developed and launched its NOVAprep® liquid-based cytology system, providing an innovative solution for cervical cancer screening. Furthermore, Novacyt SA successfully acquired Primerdesign Ltd, a molecular diagnostics company specializing in infectious diseases, expanding its product portfolio and market reach. The company also received Emergency Use Authorization from the US FDA for its COVID-19 testing kit, allowing for rapid and accurate diagnosis during the global pandemic. Novacyt SA's continuous commitment to innovation and strategic acquisitions has positioned it as a prominent player in the field of diagnostics and molecular testing.

Novacyt SA is primarily present in various countries and regions worldwide. As a global biotechnology company, Novacyt SA has established its presence in key markets such as Europe, including France, Germany, and the United Kingdom. Additionally, the company has expanded its operations into North America, with a strong focus on the United States. Novacyt SA also maintains a significant presence in other regions, including Asia, Latin America, and the Middle East. With its international reach, Novacyt SA is committed to serving the needs of customers and stakeholders across diverse geographies, contributing to its overall growth and success.

Novacyt SA is a leading international diagnostics company that prides itself on its commitment to high values and corporate philosophy. With a focus on innovation, Novacyt prioritizes providing accurate and reliable diagnostic solutions to improve global healthcare outcomes. The company's core values revolve around quality, integrity, and collaboration. Novacyt SA aims to meet the highest standards in every aspect of its operations, from research and development to manufacturing and customer support. By embracing a customer-centric approach and fostering partnerships, Novacyt SA strives to deliver impactful diagnostic solutions and contribute to the advancement of healthcare worldwide.

7 analytikere vurderer i øjeblikket Novacyt-aktien: 0 anbefaler køb, 2 hold og 5 salg. For 2026 forventer analytikere, at Novacyt genererer omsætning på 30,53 Mio. GBP og indtjening pr. aktie på -0,13 GBP.

Novacyt Analytikerens Kursmål 2026

Omregnet til den aktuelle valutakurs handles Novacyt-aktien til 0,01 EUR (0,00 GBP).

Novacyt-aktien (ALNOV.PA) er noteret på 8 børser, herunder: London (NCYT.L), Frankfurt (NYZ.F), München (NYZ.MU), Düsseldorf (NYZ.DU), Paris (ALNOV.PA).

Novacyt SA is a multinational company that offers innovative diagnostic products and services for clinical diagnostics, life science research, and biopharmaceuticals. The company specializes in the development, manufacturing, and marketing of products for the diagnostics of infectious diseases and cancer. The core business of Novacyt SA is the development and marketing of molecular diagnostic tests for a variety of infectious diseases and types of cancer. The tests are specifically used for in vitro diagnostics and are based on polymerase chain reaction (PCR) technology. The tests are designed for rapid and accurate diagnosis of infectious diseases such as Covid-19, influenza, HIV, hepatitis, and tuberculosis, as well as cancer types such as prostate cancer and lung cancer. Novacyt SA operates in two business areas: diagnostics and biopharma. In the diagnostics sector, the company develops and markets molecular diagnostic tests used for the diagnosis of infectious diseases and cancer. The products of the diagnostics business include the NOVAprep cytology supplement and the RUBIDIUM radionuclide. In the biopharma sector, Novacyt SA produces and markets recombinant proteins and antibodies for research and development of innovative therapeutics and vaccines. The products of the biopharma business include purified beta-lactamase, cystatin C, and CD20, essential components for the development of cancer therapeutics and vaccines. Novacyt SA is focused on strengthening its market position in the diagnostics and biopharma sectors through the expansion of its portfolio of diagnostic tests and the development of new products for biopharma research. Additionally, Novacyt SA continuously conducts research and development activities to bring future products for the diagnosis of infectious diseases and types of cancer to the market. Novacyt SA has a strong presence in the global market and operates in over 100 countries worldwide. The company is oriented towards collaborating with partners in Europe, the Middle East, Africa, and Asia to market its products and services in different regions across the world. Overall, Novacyt SA has structured its business model around two pillars: molecular diagnostic tests and biopharma products. The company specializes in the development of products for the diagnostics of infectious diseases and cancer and aims to expand its presence in the global market and broaden its portfolio of diagnostic tests and biopharma products.

forventet-omsætningen for Novacyt er 30,53 Mio. GBP. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Novacyt er -8,86 Mio. GBP. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Novacyt er i øjeblikket -0,04. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Novacyt-aktien.

Pris-til-salgs-forholdet (P/S) for Novacyt er i øjeblikket 0,01. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Novacyt-aktien.

AlleAktien-kvalitetsscore for Novacyt er 2/10.

ISIN for Novacyt er FR0010397232. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Novacyt er A12CFH. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Novacyt er ALNOV.PA. Tickersymbolet bruges til at handle Novacyt-aktier på børsen.